Junshi Granted US Breakthrough Status for PD-1 in Nasopharyngeal Cancer

Junshi Bio of Shanghai reported the US FDA granted Breakthrough Designation to its PD-1 for nasopharyngeal carcinoma, the first China biopharma awarded BTD for a PD-1 drug. In May of this year, the FDA granted toripalimab orphan drug designation for the same indication. Though relatively rare in the US , NPC is one of the most common malignant tumors in China . In late 2018, toripalimab became the first China-developed PD-1 approved for use in China , where it is marketed as Tuoyi for melanoma patients. More details.... Stock Symbols: (HK: 1877; SHA: 688180) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.